Vistagen Therapeutics, Inc.

Good day, everyone, and thank you for standing by. Welcome to Vistagen Therapeutics Fiscal Year 2026 First Quarter Corporate Update Conference Call-In Webcast. Please note that today's call is being recorded. At this time, I'd like to turn the call over to your host, Mark McPartland, Senior Vice President, Investor Relations at Vistagen. Mark, please go ahead.

Thank you, Justin. Good afternoon, everyone, and welcome to Vistagen's Fiscal Year 2026 First Quarter Corporate Update Conference Call-In Webcast. Earlier this afternoon, we issued a press release for our Fiscal Year 2026 First Quarter, which ended on June 30th, 2025, providing an overview of our progress on our lead clinical stage neuroscience programs. We encourage you to review the release and attend to you, which can be found on our website's Investor section. Now, before we begin, I'd like to note that we will be making four-looking statements regarding our business during today's call based on our current expectations and information. These four-looking statements speak only as of today, except as law requires, we do not assume any duty to update any four-looking statements made today or in the future. Of course, four-looking statements involve risks and uncertainties, and our actual results could differ from the current state of the country. We will be providing an overview of our progress and information from materially from those anticipated by any four-looking statements we make today. Additional information concerning our risks and uncertainties and factors that could affect our business and financial results are included in our First Quarter Fiscal Year 2026, Form 10Q, for the period ending June 30th, 2025, and in future filings that we'll make with the SEC from time to time, all of which are or will be available in Investor section of our website and

of course, on the SEC's website.